Business Description
VBI Vaccines Inc
NAICS : 325412
SIC : 3741
ISIN : CA91822J1030
Description
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | -0.07 | |||||
| Debt-to-Equity | -9.28 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -15.1 | |||||
| Beneish M-Score | 17.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 56.3 | |||||
| 3-Year EBITDA Growth Rate | 2.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13.9 | |||||
| 3-Year FCF Growth Rate | 15.6 | |||||
| 3-Year Book Growth Rate | -75.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 63.47 | |||||
| Future 3-5Y Total Revenue Growth Rate | 95.77 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.07 | |||||
| 9-Day RSI | 20.46 | |||||
| 14-Day RSI | 21.57 | |||||
| 6-1 Month Momentum % | 14.33 | |||||
| 12-1 Month Momentum % | -40.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.34 | |||||
| Quick Ratio | 0.21 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 247.68 | |||||
| Days Sales Outstanding | 9.11 | |||||
| Days Payable | 246.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.7 | |||||
| Shareholder Yield % | -40459.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -24.06 | |||||
| Operating Margin % | -505.33 | |||||
| Net Margin % | -881.79 | |||||
| FCF Margin % | -541.8 | |||||
| ROE % | -548.07 | |||||
| ROA % | -86.45 | |||||
| ROIC % | -48.25 | |||||
| ROC (Joel Greenblatt) % | -601.05 | |||||
| ROCE % | -194.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Revenue | 4.05 | |||||
| EV-to-Forward-Revenue | 4.98 | |||||
| EV-to-FCF | -0.74 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -367721.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VBI Vaccines Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 8.771 | ||
| EPS (TTM) (€) | -6.405 | ||
| Beta | 0 | ||
| Volatility % | 93.03 | ||
| 14-Day RSI | 21.57 | ||
| 14-Day ATR (€) | 0.035303 | ||
| 20-Day SMA (€) | 0.36221 | ||
| 12-1 Month Momentum % | -40.35 | ||
| 52-Week Range (€) | 0.0395 - 1.24 | ||
| Shares Outstanding (Mil) | 28.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VBI Vaccines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VBI Vaccines Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
VBI Vaccines Inc Frequently Asked Questions
What is VBI Vaccines Inc(FRA:LO9A)'s stock price today?
The current price of FRA:LO9A is €0.08. The 52 week high of FRA:LO9A is €1.24 and 52 week low is €0.04.
When is next earnings date of VBI Vaccines Inc(FRA:LO9A)?
The next earnings date of VBI Vaccines Inc(FRA:LO9A) is 2025-02-28 Est..
Does VBI Vaccines Inc(FRA:LO9A) pay dividends? If so, how much?
VBI Vaccines Inc(FRA:LO9A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers